LIFE SAVING DRUGS PROGRAM EXPERT PANEL

11th MEETING: 18 February 2022

**AGENDA**

1. **Standing business**
   1. Welcome, apologies and potential or actual Conflicts of Interest
   2. Update on actions from previous meetings
   3. Correspondence
   4. Report from the Secretariat
2. **Proposed 24 month reviews of existing LSDP medicines**
   1. Elosulfase alfa (Vimizim®) - for the treatment of Mucopolysaccharidosis (MPS) Type IVA (Morquio A)
   2. Miglustat (Zavesca®) – for the treatment of Gaucher disease
3. **Considerations of LSDP listing**
   1. Eliglustat (Cerdelga®) – for the treatment of Gaucher disease
4. **Applications for new LSDP medicines**

4.1 Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease

1. **Other business**